This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1EJ2, PDB: 1GZU, PDB: 1HYB, PDB: 1KKU, PDB: 1KQN, PDB: 1KQO, PDB: 1KR2, PDB: 1M8F, PDB: 1M8G, PDB: 1M8J, and PDB: 1M8K.
=== Imaging === The SBP-Tag will also bind to streptavidin or streptavidin reagents in solution. Applications of these engineered associations include the visualization of specific proteins within living cells, monitoring of the kinetics of the translation of individual proteins in an in vitro translation system, control of the integration of a multi-spanning membrane protein into the endoplasmic reticulum by fusing the SBP-Tag to the N-terminal translocation sequence and then halting integration with streptavidin and restarting integration with biotin. Fluorescent streptavidin reagents (e.g. streptavidin-HRP) can be used to visualize the SBP-tag by immunoblotting of SDS-PAGE. Additionally, antibodies to the SBP-tag are available commercially.
Endogenous Originating from within an organism, tissue, or cell. In neuroscience, it typically refers to naturally occurring neurotransmitters or signaling molecules. Endorphins Endogenous opioid peptides that bind to opioid receptors and act as natural painkillers and mood enhancers. Engram A theoretical physical trace or biological substrate of memory in the brain. The term is used in memory research to describe the neural changes underlying a specific memory. Enteric nervous system A subdivision of the autonomic nervous system that governs the function of the gastrointestinal system. Sometimes called the "second brain." Epinephrine A hormone and neurotransmitter (also known as adrenaline) involved in the body’s fight-or-flight response. Produced in the adrenal medulla. EPSP (Excitatory Postsynaptic Potential) A depolarizing event in a postsynaptic neuron caused by the influx of positive ions, making the neuron more likely to fire an action potential. Equilibrium potential The membrane potential at which there is no net flow of a particular ion across the cell membrane. It can be calculated using the Nernst equation. Estrogen A steroid hormone that, in addition to reproductive functions, affects brain structure, cognition, and neuroprotection, particularly in areas such as the hippocampus. Evoked potential A measured electrical response of the nervous system to a specific sensory, motor, or cognitive stimulus, commonly recorded with EEG. Excitability The ability of a neuron or muscle cell to respond to a stimulus and generate an action potential.
Bavaria (The geographically distinct Palatinate, which was part of Bavaria, 1816–1946, is now part of Rheinland Pfalz). Bremen Hamburg Hesse Saxony Thuringia The other 11 states of the Weimar Republic either merged into one another or were separated into smaller entities:
Sources: en.wikipedia.org
== Treatment == Silicosis is a permanent disease with no cure. Treatment options currently available focus on alleviating the symptoms and preventing any further progress of the condition. These include:
=== Marriages and children === Galloway has been married four times and has six children. In 1979, he married Elaine Fyffe, with whom he has a daughter. The couple separated in 1987 and divorced in 1999. In 1994, Galloway married Amineh Abu-Zayyad, a Palestinian biologist, in a non-legally binding Islamic ceremony; a legally binding civil ceremony followed in March 2000. Abu-Zayyad was granted a divorce in February 2009, after an estrangement of several years, on the grounds of "unreasonable behaviour"; her petition was not contested. Galloway married Rima Husseini, his former researcher, in a non-legally binding Islamic ceremony in 2005. Galloway had two sons with Husseini, who is from Lebanon. On 31 March 2012 he married his fourth wife, the Dutch–Indonesian anthropologist Putri Gayatri Pertiwi, then 27, in Amsterdam. The initial event was followed by a traditional Javanese wedding ceremony in Sumatra and a civil marriage at the House of Commons in September 2012. Pertiwi worked as a consultant for a Dutch research firm and as a co-presenter of Galloway's TV show Sputnik. The couple have three children.
==== Proton abstraction ==== Proton abstraction is different from the three ionization methods mentioned above because negative ions (NI) are formed during the process rather than positive ions. (M-H)− ions are often produced in polar organics in the NI mode. The first three ionization mechanisms discussed above all have their analogues in NI-FD-MS. In field ionization, molecular anions (M− ̇ ) can be generated. Anion attachment can also lead to the formation of negative ions for some molecules, for example, (M + Cl)−. Thermal desorption usually produces anion (A−) and cluster ion (e.g. CA2−) for salts.
They concluded more experimental research is needed to investigate the toxicity of mephedrone. Doctors who treated a 15-year-old female suffering from mephedrone intoxication suggested in The Lancet that, like MDMA, mephedrone may promote serotonin-mediated release of antidiuretic hormone, resulting in hyponatraemia and an altered mental state. In another case, a 19-year-old male was admitted to hospital suffering from inflammation of the heart, 20 hours after taking one gram of mephedrone. The doctors treating the patient stated it was caused by either a direct toxic effect of mephedrone on the heart muscle, or by an immune response. One case of acquired methaemoglobinaemia, where a patient had "bluish lips and fingers", has also been reported, after the user snorted one gram of mephedrone. The patient started to recover after arriving at the hospital and it was not necessary to administer any medication.
Isotope masses from: Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Sources: en.wikipedia.org
However, because CPE is not a rate-limiting enzyme for the production of most neuropeptides and peptide hormones, it is not clear how relatively modest decreases in CPE activity can cause physiological effects.
Additionally, she starred in the one-shot X-Men: Sword of the Braddocks #1 in 2009 and the solo 4-issue series X-Men: Psylocke in 2010. During the Krakoan Age, Kwannon as Psylocke appeared in various team books such as the Hellions (2020) and Marauders (2022) and then starred in the one-shot X-Men: Blood Hunt – Psylocke #1 in 2024. As part of the X-Men: From the Ashes relaunch, Kwannon joined the main X-Men team, appearing in the 2024 series X-Men. Psylocke starred in a new solo ongoing series starting in November 2024. The character has been adapted in various media incarnations, including films, television series, and video games, having most notably been portrayed by Olivia Munn in the film X-Men: Apocalypse (2016). She is voiced by Naoko Mori in the second season of X-Men '97 (2026).
In return, the host provides the symbiont with chemicals required for chemosynthesis, such as carbon, sulfide, and oxygen. In the early stages of studying life at hydrothermal vents, there were differing theories regarding the mechanisms by which multicellular organisms were able to acquire nutrients from these environments, and how they were able to survive in such extreme conditions. In 1977, it was hypothesized that the chemoautotrophic bacteria at hydrothermal vents might be responsible for contributing to the diet of suspension-feeding bivalves. Finally, in 1981, it was understood that giant tubeworm nutrition acquisition occurred as a result of chemoautotrophic bacterial endosymbionts. As scientists continued to study life at hydrothermal vents, it was understood that symbiotic relationships between chemoautotrophs and macrofauna invertebrate species was ubiquitous. For instance, in 1983, clam gill tissue was confirmed to contain bacterial endosymbionts; in 1984 vent bathymodiolid mussels and vesicomyid clams were also found to carry endosymbionts. However, the mechanisms by which organisms acquire their symbionts differ, as do the metabolic relationships. For instance, tubeworms have no mouth and no gut, but they do have a "trophosome", which is where they deal with nutrition and where their endosymbionts are found. They also have a bright red plume, which they use to uptake compounds such as O, H2S, and CO2, which feed the endosymbionts in their trophosome.
To have a better chance of detecting Type III artificial sources, Calissendorff suggests taking several photographs in a row, fast enough to fix the movement of turbulence in the atmosphere, applying different photometric filters and looking for dark areas (the case of a Dyson sphere being assembled by a Type II civilization), or analyzing the infrared spectrum of galaxies. A much larger sample of objects should be studied.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.